- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07637214
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
June 5, 2026 updated by: Meifang Han, Tongji Hospital
Curative Effect Analysis of Antiviral Therapy in CHB Patients Over 30 Years Old With HBV DNA Positive and Normal ALT
This is a prospective observational study of CHB patients who have not received antiviral treatment but HBV DNA are positive.Investigators aim to explore the antiviral effect and influencing factors of patients over 30 years old with normal ALT level after receiving antiviral treatment.
Study Overview
Status
Completed
Conditions
Detailed Description
In the past, clinicians thought that patients with chronic hepatitis B with normal ALT should be followed up regularly and not be treated with antiviral therapy for the time being, but more and more studies show that if antiviral therapy is not started in time, these patients still have a relatively high risk of cirrhosis and HCC.
Therefore, the current Chinese guideline recommends that patients over the age of 30 with HBV DNA positive need antiviral treatment even if their ALT levels are normal.
In this study, investigators aim to observe the antiviral effect of CHB patients above 30 years old and normal liver function.
CHB patients were divided into NAs (TMF, ETV, or TAF) treatment and untreated groups for follow-up.
Then, participants who achieved HBV DNA negative and HBsAg <3000 IU/ml after 12 weeks of NAs therapy could choose either NAs combined with 48 weeks of pegylated interferon α-2b(Peg-IFNα-2b) therapy or continue NAs monotherapy.
Follow-ups were conducted every 12-24 weeks for a total duration of 96 weeks.
Dynamic observations included monitoring virological markers,biochemical indicators,liver stiffness measurement(LSM),and controlled attenuation parameter(CAP) throughout the study period.
After obtaining the informed consent of participants, the serum of participants and PBMC of some participants were collected for further study,so that investigators are able to explore the serological indexes related to curative effect and the immune function of participants before and after treatment.
Study Type
Observational
Enrollment (Actual)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Tongji Hospital,Wuhan,Hubei
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The research population is CHB patients who have never received antiviral treatment and come to Tongji hospital for consultation and reexamination.
Description
Inclusion Criteria:
- CHB patients over 30 years old ;
- HBV DNA >20IU/ml and ALT level ≤40U/L;
- All of them have never received any antiviral treatment(including NAs and interferon-α)。
Exclusion Criteria:
- pregnancy status;
- Patients with compensated/decompensated cirrhosis and liver cancer have been diagnosed by imaging or other indicators;
- HCV, HIV, EB virus/cytomegalovirus infection, schistosomiasis liver disease, drug-induced liver injury, autoimmune hepatitis and alcoholic liver disease;
- Use immunosuppressants ;
- Previous history of liver cancer, organ transplantation and alcoholism (male ≥30 g/d, female ≥20 g/d);
- Insufficient follow-up time and imperfect clinical/laboratory informations;
- Combined with other major diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
NA treatment
NA treated with TDF,ETV OR TMF
|
|
Control group without antiviral treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
48-week HBV DNA negativity rate(%)
Time Frame: 48 weeks
|
HBV DNA negative rate(%) at 48 weeks
|
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
48-week ALT normalization rate(%)
Time Frame: 48 weeks
|
ALT normalization rate(%) at 48 weeks
|
48 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Degree of improvement in liver fibrosis
Time Frame: 48 weeks
|
Changes in liver stiffness measurement (LSM) by FibroScan were used to describe changes in patients' liver fibrosis
|
48 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Meifang Han, Doctor, Tongji Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 13, 2023
Primary Completion (Actual)
March 13, 2024
Study Completion (Actual)
June 13, 2025
Study Registration Dates
First Submitted
April 13, 2026
First Submitted That Met QC Criteria
June 5, 2026
First Posted (Actual)
June 9, 2026
Study Record Updates
Last Update Posted (Actual)
June 9, 2026
Last Update Submitted That Met QC Criteria
June 5, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Organizing Pneumonia
- Immune System Diseases
- Infections
- Virus Diseases
- Respiratory Tract Diseases
- Digestive System Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- DNA Virus Infections
- Hepadnaviridae Infections
- Bronchiolitis Obliterans
- Bronchiolitis
- Bronchitis
- Hepatitis
- Graft vs Host Disease
- Bronchiolitis Obliterans Syndrome
- Hepatitis B
Other Study ID Numbers
- ALTN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.